Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC)

1. Lordick, F.
2. Peeters, M.
3. Price, T.
4. Hotko, Y.
5. Cervantes, A.
6. Ducreux, M.
7. Andre, T.
8. Chan, E.
9. Rong, A.
10. Gansert, J.